Download PDF
Thromb Haemost 2008; 100(05): 905-911
DOI: 10.1160/TH08-05-0339
Cellular Proteolysis and Oncology
Schattauer GmbH

Elevated white blood cell count and outcome in cancer patients with venous thromboembolism

Findings from the RIETE Registry[*]
Javier Trujillo-Santos
1   Department of Internal Medicine, Hospital Universitario Santa María de Rosell, Cartagena, Murcia, Spain
,
Pierpaolo Di Micco
2   Internal Medicine and Emergency Room, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy
,
Mariateresa Iannuzzo
3   Department of Epidemiology, Fatebenefratelli Hospital, Naples, Italy
,
Ramón Lecumberri
4   Department of Haematology, Clinica Universitaria de Navarra, Pamplona, Spain
,
Ricardo Guijarro
5   Departament of Internal Medicine, Hospital Universitario Carlos Haya, Málaga, Spain
,
Olga Madridano
6   Departament of Internal Medicine, Hospital La Paz, Madrid, Spain
,
Manuel Monreal
7   Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
,
for the RIETE Investigators › Author Affiliations
Further Information

Publication History

Received 30 May 2008

Accepted after minor revision 12 August 2008

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

Summary

A significant association between elevated white blood cell (WBC) count and mortality in patients with cancer has been reported,but the predictive value of elevatedWBC on mortality in cancer patients with acute venous thromboembolism (VTE) has not been explored. RIETE is an ongoing registry of consecutive patients with acute VTE. We compared the three-month outcome of cancer patients with acuteVTE according to theirWBC count at baseline. As of May 2007, 3805 patients with active cancer and acuteVTE had been enrolled in RIETE. Of them, 215 (5.7%) had low- (<4,000 cells/µl), 2,403 (63%) normal- (4,000–11,000 cells/µl), 1,187 (31%) elevated (>11,000 cells/µl) WBC count. During the study period 190 patients (5.0%) had recurrent VTE, 156 (4.1%) major bleeding, 889 (23%) died (399 of disseminated cancer, 113 of PE, 46 of bleeding. Patients with elevated WBC count at baseline had an increased incidence of recurrent VTE (odds ratio [OR]: 1.6; 95% confidence interval [CI]:1.2–2.2),major bleeding (OR:1.5;95% CI:1.1–2.1) or death (OR:2.7;95% CI:2.3–3.2).Most of the reported causes of death were significantly more frequent in patients with elevated BC count.Multivariate analysis confirmed that elevated WBC count was independently associated with an increased incidence of all three complications. In conclusion, cancer patients with acute VTE and elevated WBC count had an increased incidence of VTE recurrences,major bleeding or death. This worse outcome was consistent among all subgroups and persisted after multivariate adjustment.

Keywords

Cancer - leukocytosis - venous thromboembolism - outcome

* A full list of RIETE investigators is given in the Appendix.


 

  • References

  • 1 Levitan N, Dowlati A, Remick S. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78: 285-291.
    CrossrefPubMedGoogle Scholar
  • 2 Carson JL, Kelley MA, Duff A. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
    CrossrefPubMedGoogle Scholar
  • 3 Prandoni P, Lensing AW, Cogo A. et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
    CrossrefPubMedGoogle Scholar
  • 4 Sorensen H, Mellemkjaer L, Olsen J. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
    CrossrefPubMedGoogle Scholar
  • 5 Kasuga I, Makino S, Kiyokawa H. et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001; 92: 2399-2405.
    CrossrefPubMedGoogle Scholar
  • 6 Maltoni M, Caraceni A, Brunelli C. et al. Prognostic factors in advanced cancer patients: Evidencebased clinical recommendations. A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23: 6240-6248.
    CrossrefPubMedGoogle Scholar
  • 7 Shankar A, Wang JJ, Rochtchina E. et al. Association between circulating white blood cell count and cancer mortality. Arch Intern Med 2006; 166: 188-194.
    CrossrefPubMedGoogle Scholar
  • 8 Gripp S, Moeeler S, Bölke E. et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007; 25: 3313-3320.
    CrossrefPubMedGoogle Scholar
  • 9 Monreal M, Falgá C, Valdés M. et al. For the RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE registry. J Thromb Haemost 2006; 04: 1950-1956.
    CrossrefPubMedGoogle Scholar
  • 10 Falgà C, Capdevila JA, Soler S. et al. for the RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE Registry. Thromb Haemost 2007; 98: 771-776.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Blanco-Molina A, Trujillo-Santos J, Criado J. et al. and the RIETE Investigators. Venous thrombo-embolism during pregnancy or postpartum: Findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Arcelus JI, Monreal M, Caprini JA. et al. and the RIETE investigators. Clinical presentation and timecourse of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost 2008; 99: 546-551.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Muñoz FJ, Mismetti P, Poggio R. et al. for the RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis: Results from the RIETE Registry. Chest 2007; 133: 143-148.
    PubMedGoogle Scholar
  • 14 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
    CrossrefPubMedGoogle Scholar
  • 15 Weeks JC, Cook EF, O’Day SJ. et al. Relationship between cancer patient’s predictions of prognosis and their treatment preferences. J Am Med Assoc 1998; 279: 1709-1714.
    CrossrefPubMedGoogle Scholar
  • 16 Christakis NA, Lamont EB. Extent and determinants of error in doctor’s prognoses in terminally ill patients: Prospective cohort study. Br Med J 2000; 320: 469-472.
    CrossrefPubMedGoogle Scholar
  • 17 Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer: J Am Med Assoc. 2003; 290: 98-104.
    PubMedGoogle Scholar
  • 18 Vigano A, Dorgan M, Buckingham J. et al. Survival prediction in terminal cancer patients: A systematic review of the medical literature. Palliat Med 2000; 14: 363-374.
    CrossrefPubMedGoogle Scholar
  • 19 Lin J, Proctor MC, Varma M. et al. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg 2003; 37: 976-983.
    CrossrefPubMedGoogle Scholar
  • 20 Henke PK, Wakefield TW, Kadell AM. et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001; 99: 84-91.
    CrossrefPubMedGoogle Scholar
  • 21 Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13: 34-39.
    CrossrefPubMedGoogle Scholar
  • 22 Landolfi R, Di Gennaro L, Barbui T. et al. for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Blood. 2007; 109: 2446-2452.
    PubMedGoogle Scholar